We would love to hear your thoughts about our site and services, please take our survey here.
No need to be so miserable DocDan. Just facts, nothing to be afraid of. Any investor would be thrilled with the knowledge that SNG001 is not reliant on any one venue, but multiple indications. Derisked investment; I would have thought you'd be thrilled?
DocDan,
I's not really an issue - we are now a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta (IFN-β) for the treatment of severe viral lung infections as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs. We've moved on from being a Covid-centric treatment, which is great, given your analysis of the current Covid landscape.
The never ending drama.
If you don't have health insurance in America you need to access the 'Bridge Access Program' to get the vaccine for free. Importantly - that programme will end on December 31, 2024, so any governmental aid is essentially temporary.
The Biden Administration has not guaranteed to extend it beyond that date, and if the fake-tanned one somehow wrangles his way out of 96 endictments and back into the Oval office, then you can probably say, with a fair amount of certainty, that a 2nd Trump Administration won't spend a dime on anything remotely in the interests of public health. So this time next year, those 25-30 million uninsured could be looking at $100+ for vaccine, then there's the follow-up boosters necessitated because of variant changes, etc. Unless you think Covid is going o magically disappear as the orange one does, that cost is going to be hanging over them until the day they die, and for a family that cost is not negligible.
So yes, there will always be a target group for an antiviral like SNG001.
The article fails to address, or addresses too likely imo, the most likely causes, namely being one of cost (Americans now have to pay out of pocket fr vaccinations and it's not a cheap recurring expense for the majority of whom live paycheck to paycheck), the prevalence of auto-abs in the population (rendering other precautions less successful), and continued widespread misinformation on vaccines and treatments.
When you knowingly throw out misleading pricing information, expect it to be called out as inaccurate. Facts matter, as you well know.
I think you need to take a break DocDan. You are wittering on about something I don't recognise. Perhaps it is your perception of reality that is skewed?
Another deranged, not to mention deeply inaccurate and slanderous post that merits little attention.
The only thing that is "perverse" here, is your warped fixation with untruths.
Price comparisons to any Covid-only drug is immaterial. It's apples and pears, whatever way you slice it.
"of all the outpatient drugs you listed SNG was the most expensive by a factor of at least 7."
A wholly misleading statement, but moreover, a very moot point, because SNG001 is destined for inpatients, not for mild outpatient cases who would take those drugs.
Very much apples and pears.
...And yes, I've mixed up my Paxlovid with my Molnupiravir. Silly me. No shoot!
However, latest research remains valid - even though there are treatments for Covid, research is still uncovering weaknesses in those and new treatments are still needed.
But the
Https://www.phc.ox.ac.uk/news/new-study-suggests-antiviral-treatment-course-is-not-long-enough-to-treat-covid-19-in-at-risk-patients
Be aware that it is not a magic bullet, and latest studies (published yesterday) , underline the need for less problematic treatments. The hunt is still on for an antiviral that does not compomise the immune system, as Paxlovid is now shown to do in some patients:
"It potentially means molnupiravir-treated participants would be susceptible to re-infection sooner than the patients who received usual care. "These findings raise important questions about the impact of molnupiravir on patients' immunity," said Dr Oliver van Hecke, Senior Clinical Research Fellow at the University of Oxford and co-author of the study. "Even if taking molnupiravir for longer fully gets rid of the virus, some patients might still develop weaker protection against catching it again in the future. It would be useful to explore whether molnupiravir together with other antiviral drugs in combination better eliminates the virus, and ensures patients build up good immunity against it. This could help prevent treated patients from catching it again soon after and also reduce the chance of passing on mutated viral strains." These findings, say the authors, could help policy makers shape future antiviral treatment strategies and should inform future trials for COVID-19 treatments.
"Conclusion. Inhaled SNG001 upregulated lung antiviral defenses as assessed using sputum cell biomarker responses and accelerated viral clearance, supporting the
proposed mechanism of action as an antiviral treatment for severe viral lung
infections"
Thanks Aether I wasn't aware of that confirmation from AZ. By what do they mean 'TMG'?
Yes I do note AZ history/role here - my response to Spacman was (hopefully) making the point that IMHO Janssen may not be the only rodeo in town. If we do collaborate/partner/whatever, it could be with *any* suitable BP in the respiro space.
I can't see any asset sale being applicable here. This is a spin-out from academia, not a traditional wholly economic start-up. The founders are the originators of the intellectual property, they are still University personnel. Complicated. The Biobank is also an extremely interesting one. You can't just buy and sell human tissue, to my knowledge. If a University spin-out was an animal, I'd be tempted to call it a bit of a protected species....
As for J&J, worth remembering that they are just one possible BP 'interest'. But we don't know for sure who may end up being a partner or collaborator, beyond the Janssen/Synairgen Universal link. Could it end up just as easily being GSK in the frame? Or Sanofi? Or Roche? Or a mix? Or none? Who knows?
Maybe it's just me DocDan but if I were a BP and I was part/fully-funding (or owning, or aiming to acquire) a company that produce such assays, I might also be in the market for another company that use those assays, in order to determine treatment, for a potential blockbuster treatment that they are developing. Dunno. Seems logical to me. Attractive even....
That's not an answer Mani, it's a load of fluffy fluff McFluffystuff (otherwise known as gibberish). IMHO!
Let's have some figures then, just a guesstimate for the potential global market will do.
Be careful there Tommy, you're making a very convincing business case for SNG001!!
Mani(facturo), As for your "lesson in manufacturing", .... who knew SNG will never be commercial"? Tell me, is that why you invested here? LOL.
So what are your figures Mani? How do you arrive that that conclusion? How many units do you see being needed of SNG001, to meet the urgent need for the treatment of severe viral lung infections globally. Hundreds? Thousands? hundreds of thousands? Millions? Tens of millions? What data are you working off for your costings? Let's be having it. Time to put your money where your mouth is and back up your claims with actual real-life workings.
SO ?